• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

    9.520 -0.020 (-0.21%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 31,656
    Open 9.350
    Bid (Size) 9.300 (200)
    Ask (Size) 10.24 (100)
    Prev. Close 9.540
    Today's Range 9.305 - 9.970
    52wk Range 5.349 - 15.08
    Shares Outstanding 11,586,406
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
     
    Via Benzinga

    Performance

    YTD
    -14.7%
    -14.7%
    1 Month
    -13.3%
    -13.3%
    3 Month
    +29.3%
    +29.3%
    6 Month
    +46.7%
    +46.7%
    1 Year
    -30.9%
    -30.9%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
    From Tempest Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
    From Tempest Therapeutics
    Via GlobeNewswire
    Let's uncover which stocks are experiencing notable gaps during today's session.
    Via Chartmill
    Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Get insights into the top gainers and losers of Monday's pre-market session.
    Via Chartmill
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
    Via Benzinga
    Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger
    Via Stocktwits
    Topics World Trade
    Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
    From Tempest Therapeutics
    Via GlobeNewswire
    Monday's session: gap up and gap down stocks
    Via Chartmill
    Tempest Reports Year End 2024 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tuesday's after hours session: top gainers and losers
    Via Chartmill
    Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Tempest Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Tempest Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Tempest Therapeutics, Inc. - Common Stock trade on?
    Tempest Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tempest Therapeutics, Inc. - Common Stock?
    The ticker symbol for Tempest Therapeutics, Inc. - Common Stock is TPST on the Nasdaq Stock Market
    What is the current price of Tempest Therapeutics, Inc. - Common Stock?
    The current price of Tempest Therapeutics, Inc. - Common Stock is 9.520
    When was Tempest Therapeutics, Inc. - Common Stock last traded?
    The last trade of Tempest Therapeutics, Inc. - Common Stock was at 11/07/25 04:00 PM ET
    What is the market capitalization of Tempest Therapeutics, Inc. - Common Stock?
    The market capitalization of Tempest Therapeutics, Inc. - Common Stock is 110.30M
    How many shares of Tempest Therapeutics, Inc. - Common Stock are outstanding?
    Tempest Therapeutics, Inc. - Common Stock has 110M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.